Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma

by NASDAQ Market News September 30, 2019

NASDAQ Market News
Click here to email author

Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita® (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH)

Global $1.44Bn Lancets Market by Type, Application, End-user & Region – Forecast to 2024

Ads